The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Efficacy of Oral Cochleate-Amphotericin B in a Mouse Model of Systemic Candidiasis
Open accessAbstract
Amphotericin B (AMB) remains the principal therapeutic choice for deep mycoses. However, its application is limited by toxicity and a route of administration requiring slow intravenous injection. An oral formulation of this drug is desirable to treat acute infections and provide prophylactic therapy for high-risk patients. Cochleates are a novel lipid-based delivery system that have the potential for oral administration of hydrophobic drugs. They are stable phospholipid-cation crystalline structures consisting of a spiral lipid bilayer sheet with no internal aqueous space. Cochleates containing AMB (CAMB) inhibit the growth of Candida albicans, and the in vivo therapeutic efficacy of CAMB administered orally was evaluated in a mouse model of systemic candidiasis. The results indicate that 100% of the mice treated at all CAMB doses, including a low dosage of 0.5 mg/kg of body weight/day, survived the experimental period (16 days). In contrast, 100% mortality was observed with untreated mice by day 12. The fungal tissue burden in kidneys and lungs was assessed in parallel, and a dose-dependent reduction in C. albicans from the kidneys was observed, with a maximum 3.5-log reduction in total cell counts at 2.5 mg/kg/day. However, complete clearance of the organism from the lungs, resulting in more than a 4-log reduction, was observed at the same dose. These results were comparable to a deoxycholate AMB formulation administered intraperitoneally at 2 mg/kg/day (P < 0.05). Overall, these data demonstrate that cochleates are an effective oral delivery system for AMB in a model of systemic candidiasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Orally administered MAT2203 prevented death”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [119]
In the citing paper
“reduced tissue fungal burden in mice with invasive candidiasis [119,120]”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [119]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Beck‐Sagué, C. M., Jarvis, W. R., & System, N. N. I. S. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Amphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,013
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance
Hong Nguyen, M., Peacock, J. E., Morris, A. J., Tanner, D. C., Nguyen, M. L., Snydman, D. R., Wagener, M. M., Rinaldi, M. G., & Yu, V. L. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(95)00010-0 · Cited by 758
Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.
Fraser, V. J., Jones, M., Dunkel, J., Storfer, S., Medoff, G., & Dunagan, W. C. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.3.414 · Cited by 679
Walsh, T. J., Hiemenz, J. W., Seibel, N. L., Perfect, J. R., Horwith, G., Lee, L., Silber, J. L., DiNubile, M. J., Reboli, A. C., Bow, E. J., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/516353 · Cited by 623
Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles
Papahadjopoulos, D., Vail, W. J., Jacobson, K., & Poste, G. H. (1975) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(75)90299-0 · Cited by 542
Amphotericin B: current understanding of mechanisms of action
Brajtburg, J., Powderly, W. G., Kobayashi, G. S., & Medoff, G. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.2.183 · Cited by 503
Prospective Multicenter Surveillance Study of Funguria in Hospitalized Patients
Kauffman, C. A., Vazquez, J. A., Sobel, J. D., Gallis, H. A., McKinsey, D. S., Karchmer, A. W., Sugar, A. M., Sharkey, P. K., Wise, G. J., Mangi, R., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/313583 · Cited by 483
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404
Lipid Formulations of Amphotericin B: Clinical Efficacy and Toxicities
Wong‐Beringer, A., Jacobs, R. A., & Guglielmo, B. J. (1998) · Clinical Infectious Diseases · doi:10.1086/514704 · Cited by 394
Research works printed but not linked: 1
- Zarif L. Segarra L. Jin T. Scolpino A. Hyra D. Perlin D. S. Graybill J. R. Mannino R. J. Oral and systemic delivery of AmB mediated by cochleates. AAPS PharmSci. 1 1999 S-453
Cited by
Sorted by citations
An insight into the antifungal pipeline: selected new molecules and beyond
Ostrosky-Zeichner, L., Casadevall, A., Galgiani, J. N., Odds, F. C., & Rex, J. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3074 · Cited by 432
Recent advances in leishmaniasis treatment
Tiuman, T. S., Santos, A. O., Ueda‐Nakamura, T., Filho, B. P. D., & Nakamura, C. V. (2011) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2011.03.021 · Cited by 350
Antifungal drug resistance to azoles and polyenes
Canuto, M. M., & Rodero, F. G. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00371-7 · Cited by 310
Lemke, A., Kiderlen, A. F., & Kayser, O. (2005) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-005-1955-9 · Cited by 307
Amphotericin B Formulations and Drug Targeting
Torrado, J. J., Espada, R., Ballesteros, M. P., & Torrado, S. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21179 · Cited by 306
Metadata
- Authors
- Santangelo, R., Paderu, P., Delmas, G., Chen, Z.-W., Mannino, R., Zarif, L., & Perlin, D. S.
- Affiliations
- <!--label omitted: 1-->Public Health Research Institute, New York, New York, 10016,1 and
- <!--label omitted: 2-->BioDelivery Science Inc. UMDNJ, Newark, New Jersey 071032
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2000-09
- Volume
- 44
- Issue
- 9
- Pages
- 2356-2360
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC90069
- OpenAlex
- W2004315110
- Cited by
- 150
- References
- 44
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 6 · 2023: 5 · 2022: 13 · 2021: 13 · 2020: 13 · 2019: 5 · 2018: 3 · 2017: 10 · 2016: 2 · 2015: 3 · 2014: 6 · 2013: 7 · 2012: 4
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- U.S. Public Health Service
- National Institute of Allergy and Infectious Diseases (R43AI046040, R43-AI-46040)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- amphotericin B, cochleates, oral drug delivery, systemic candidiasis, Candida albicans, lipid-based drug delivery, antifungal therapy, mouse model
- MeSH terms
- Administration, Oral, Amphotericin B, Animals, Antifungal Agents, Candidiasis, Chemistry, Pharmaceutical, Delayed-Action Preparations, Disease Models, Animal, Drug Carriers, Female, Kidney, Lung, Mice, Inbred BALB C, Drug Delivery Systems, Treatment Outcome, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
